新辅助同步放化疗对局部进展期食管鳞癌患者降期率的影响

Effect of neoadjuvant concurrent chemoradiotherapy on the decline rate of patients with locally advanced esophageal squamous cell carcinoma

目的探究新辅助同步放化疗对局部进展期食管鳞癌患者降期率的影响。方法选取2017年1月至2019年5月在本院收治的局部进展期食管鳞癌患者80例作为研究对象,采取单双数字法分为两组,每组40例。对照组采用新辅助化疗(紫杉醇+顺铂),实验组采用新辅助同步放化疗(放疗+紫杉醇+顺铂),比较两组患者治疗有效率、降期率以及不良反应发生率。结果实验组治疗有效率(80.0%)明显高于对照组(52.5%),差异有统计学意义(P<0.05);实验组降期率(92.5%)明显高于对照组(70.0%),差异有统计学意义(P<0.05);实验组不良反应发生率(12.5%)明显低于对照组(7.5%),但差异无统计学意义。结论对局部进展期食管鳞癌患者采用新辅助同步放化疗方法,可显著提高临床治疗有效率和降期率,且不增加不良反应发生率,安全性高,值得临床推广应用。

Objective To explore the effect of neoadjuvant chemoradiotherapy on the decline rate of patients with locally advanced esophageal squamous cell carcinoma. Methods 80 cases of patients with locally advanced esophageal squamous cell carcinoma admitted in our hospital from January 2017 to May 2019 were selected as the research subjects. The patients were divided into two groups according to single and double number methods, with 40 cases in each group. The control group was treated neoadjuvant chemotherapy(paclitaxel+cisplatin). The experimental group was treated neoadjuvant concurrent chemoradiotherapy(radiotherapy+paclitaxel+cisplatin). The treatment efficiency, the decline rate and the incidence of adverse reactions were compared between the two groups. Results The treatment efficiency of the experimental group(80.0%) was higher than the control group(52.5%), the difference was statistically significant difference(P<0.05). The rate of decline in the experimental group(92.5%) was higher than that of the control group(70.0%), the difference was statistically significant difference(P<0.05). The incidence of adverse reactions in the experimental group(12.5%) was lower than the control group(7.5%), but there was no significant difference between two groups. Conclusion The use of neoadjuvant concurrent chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma can better improve the efficiency of clinical treatment and increase the rate of decline. Compared with neoadjuvant chemotherapy, it does not increase the incidence of adverse reactions,has high safety, and is worth promoting application.